

In the Specification:

On page 1, in the title, please insert --Antibodies to-- before "Cell Cycle Regulatory";
please delete all text in the section entitled *Related Applications* and insert
therefor:

9
This application is a continuation of application number 08 /893,274 , filed on July 15,
1997, now U.S. Patent No. 5,968,821, which is a continuation of 08/306,511 filed 9/14/94, now
U.S. Patent No. 5,962,316; which is a continuation-in-part of 08/248,812 filed 5/25/94, now U.S.
Patent No. 5,889,169; which is a continuation-in-part of 08/227,371 filed 04/14/94; which is a
continuation-in-part of 08/154,915 filed 11/18/93; which claims priority to PCT/US93/09945,
filed 10/18/93, and is a continuation-in-part of 07/991,997 filed 12/17/92 (abandoned); which is a
continuation-in-part of 07/963,308 filed 10/16/92.

On page 4, line 33, after the term "Arg-Xaa-Ala-Xaa-Gly" insert --(SEQ ID No. 11)--;
on page 5, line 7, after the term "Ser-Asp-Ile-Pro-Asp;" insert --(SEQ ID No. 12)--;
line 17, after the term "Xaa-Ala-Xaa-Gly-Asp," insert --(SEQ ID No. 13)--;
line 26, after the term "Ser-Gln-Glu-Gln-Ser.", insert --(SEQ ID No. 14)--;
on page 9, line 6, after the term "(T/K)-V(F/Y)KARD", insert --(SEQ ID No. 15)--;
line 7, after the term "(F/Y)KARD", insert --(SEQ ID No. 16)--;
line 8, after the term "KARD", insert --(SEQ ID No. 17)--;
line 31, after the term "p16 cDNA", insert --(SEQ ID No. 18)--;
line 32, after the term "exon 1.", insert --(p16ex1 (SEQ ID No. 19),
p16ex13 (SEQ ID No. 20), p16nt2 (SEQ ID No. 21), p16nt3 (SEQ
ID No. 22))--;
line 33, after the term "exon 2.", insert --(p16int (SEQ ID No. 23),
p16ex15 (SEQ ID No. 24), p16ex2 (SEQ ID No. 25), p16ex14
(SEQ ID No. 26))--;
on page 10, line 2, after the term "exon 3.", insert --(p16EX5 (SEQ ID No. 27),
p16EX9 (SEQ ID No. 28), p16EX4 (SEQ ID No. 29), p16EX6
(SEQ ID No. 30), p16EX6A (SEQ ID No. 31))--;

line 8, after the term "p16", insert --(SEQ ID No. 32)--.

line 8, after the term "p15", insert --(SEQ ID No. 33)--.

line 8, after the term "p13.5", insert --(SEQ ID No. 34)--.

line 23, delete "uncouples" and insert therefor --uncoupled--;

on page 24, line 20, delete "pBlueBac" and insert therefor --pBLUEBAC--;

on page 28, line 38, after the term "Xaa(23)-Ala-Xaa(24)-Gly", insert --(SEQ ID No. 11)--;

on page 59, line 3, delete "pBluescript" and insert therefor --pBLUESCRIPT--;

line 7, delete "Fujix" and insert therefor --FUJIX--;

line 31, delete "propidium" and insert therefor --propidium--; and

line 33, delete "Axiphot" and insert therefor --AXIOPHOT--.

Please replace pages 65-74 with the amended sequence listing on the replacement enclosed herewith (pages 65-87), and renumber the claims and abstract accordingly.

In the Claims:

For the convenience of the Examiner, all claims whether are not amended are presented below for reconsideration.

11. (Amended) An antibody preparation specifically reactive with an epitope of [the immunogen of claim 10] an immunogen comprising a substantially pure preparation of a cell regulatory (CCR) protein or a fragment thereof which specifically binds to a cyclin dependent kinase (CDK), the full length form of said CCR-protein having an approximate molecular weight in the range of 14.5kD to 16kD, in an immunogenic preparation, said immunogen being capable of eliciting and immune response specific for said CCR-protein

58. (Reiterated) An isolated antibody, or fragment thereof, specifically immunoreactive with a cell cycle regulatory (CCR) protein, wherein said protein comprises at least four ankyrin-repeats and specifically binds to a cyclin-dependant kinase.